Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Teresa Coelho et al.|New England Journal of Medicine|2018Cited by 2.9k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesPablo García‐Pavía, Aleš Linhart, Claudio Rapezzi et al.|European Heart Journal|2021Cited by 1.1k
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseasesPablo García‐Pavía, Aleš Linhart, Claudio Rapezzi et al.|European Journal of Heart Failure|2021Cited by 330
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin AmyloidPablo García‐Pavía, Thibaud Damy, Erwan Donal et al.|New England Journal of Medicine|2023Cited by 233